According to the company's terms, if you are deemed ineligible, you will receive a 100% refund of any fees paid
Then came ACHIEVE-3 , published in The Lancet in February 2026, the first direct head-to-head comparison between two oral GLP-1 therapies
The degree of laxity depends on several factors, including age, genetics, the speed of weight loss, and the length of time the skin was previously stretched
One has to be prepared to take it for years, maybe even life-long, I tell them
Caruso, M.I
10.1038/onc.2017.38 Summary Keywords alcohol-associated liver disease (ALD), glucagon-like peptide 1 receptor agonists (GLP-1 RAs), metabolic dysfunction and alcohol-associated liver disease (MetALD), metabolic dysfunction-associated steatotic liver disease (MASLD), steatotic liver disease (SLD) Citation Mahalingam S, Kharbanda KK, Casey CA and Rasineni K (2026) Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum
